Prospective multicenter observational study; Safety of influenza vaccination for the lung cancer patients treated with immune-checkpoint inhibitor

Prospective multicenter observational study; Safety of influenza vaccination for the lung cancer patients treated with immune-checkpoint inhibitor - Safety of influenza vaccination for the lung cancer patients treated with immune-checkpoint inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034646

Enrollment

200

Registered

2018-11-01

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Written informed consent Advanced or relapsed non-small cell lung cancer Administration of immune-checkpoint inhibitor

Exclusion criteria

Exclusion criteria: History of severe immune-related adverse event Immune-checkpoint inhibitor has been already stopped. Administration of steroid and/or immunnosuppresive therapy Influenza infection within 2 month Anti-influenza therapy within 2 month Comorbidities of active infectious disease

Design outcomes

Primary

Measure	Time frame
incidence rate of severe immune-related adverse event after influenza vaccination among the lung cancer patients treated with immune-checkpoint inhibitor	—

Secondary

Measure	Time frame
incidence rate of severe immune-related adverse event without influenza vaccination among the lung cancer patients treated with immune-checkpoint inhibitor and incidence rate of influenza infection	—

Countries

Japan

Contacts

Public ContactKenichi Chikamori

NHO Yamaguchi-Ube Medical Center Medical Oncology

chikamori@yamaguchi-hosp.jp0836-58-2300

Outcome results